Clinical trials
Completed Primary Immunodeficiency Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 5 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baxalta now part of Shire | 9 |
| Grifols Therapeutics LLC | 6 |
| Octapharma | 6 |
| CSL Behring | 5 |
| Bio Products Laboratory | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| ADMA Biologics, Inc. | 2 |
| Kedrion S.p.A. | 2 |
| National Human Genome Research Institute (NHGRI) | 2 |
| Takeda | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Immunodeficiency Diseases | 58 |
| Common Variable Immunodeficiency | 7 |
| Immunologic Deficiency Syndromes | 7 |
| Wiskott-Aldrich Syndrome | 7 |
| Hyper-IgM Immunodeficiency Syndrome | 5 |
| Agammaglobulinemia | 4 |
| Severe Combined Immunodeficiency | 3 |
| Ciliary Motility Disorders | 2 |
| Immune System Diseases | 2 |
| Kartagener Syndrome | 2 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.